Long Term Evaluations of First Single-dose Rituximab in Children with Steroid-Dependent Minimal-Change Nephrotic Syndrome
The first single-dose rituximab treatment for children with SD-MCNS was effective and safe. Greater efficacy was observed in patients who were older at rituximab treatment onset, had a lower steroid-dependent dosage, or had a higher CD4<sup>+</sup> T-cell count before rituximab treatment. In contrast, younger male patients with a higher IgE level experienced an increased occurrence of relapse.
Authors
- Dan Feng (ORCID: https://orcid.org/0000-0002-0311-8990)
- Wenyan Huang (ORCID: https://orcid.org/0000-0002-2197-0781)
- Yun-Fan Gu
- Xinyu Kuang (ORCID: https://orcid.org/0000-0002-0528-9136)
- Sheng Hao (ORCID: https://orcid.org/0000-0003-3971-7108)
- Ping Wang (ORCID: https://orcid.org/0000-0002-1557-0394)
- Xiaoling Niu
Institutions
- Shanghai Jiao Tong University (CN)
- Shanghai Children's Hospital (CN)
Publication Details
- Journal
- Renal Failure
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1080/0886022x.2024.2427173
- Citations
- 1
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.34
Funders
- National Natural Science Foundation of China